# K060001

# Attachment 4

JAN 2 0 2006

Summary of Safety and Effectiveness Bio-Rad Laboratories, Inc.

# Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K

# Submitter:

Bio-Rad Laboratories, Inc. Clinical System Division 4000 Alfred Nobel Drive, Hercules, California 94547 Phone: (510) 741-5309 FAX: (510) 741-6471

# Contact Person:

Jackie Buckley Regulatory Affairs Representative

# Date of Summary Preparation:

December 30, 2005

Device Name:

Bio-Rad D $1 0 ^ { \mathrm { T M } }$ Dual Program Bio-Rad D-10TM Hemoglobin A1c Program on the D-10 Hemoglobin System with D-10 Rack Loader

# Classification Name:

$\mathrm { H b A } _ { \mathrm { l c } }$ : Assay, Glycosylated Hemoglobin [21CFR 864.7470 / Prod. Code LCP] and

$\mathrm { H b A } _ { 2 }$ : Hemoglobin $\mathsf { A } _ { 2 }$ Quantitation [21CFR 864.7400 / Prod. Code: JPD]

# Predicate Devices:

D-10 Hemoglobin A1c Program Bio-Rad Laboratories, Inc. [K031043, August 27, 2003]

D-10 Dual Program Bio-Rad Laboratories, Inc [K041444, June 9, 2004]

# Indications for Use Statements and Intended Uses:

The D-10TM Hemoglobin A1c Program is intended for the percent determination of hemoglobin Alc in human whole blood using ion-exchange high performance liquid chromatography (HPLC).

The D-10 Hemoglobin Alc Program is intended for use only with the Bio-Rad D-10 Hemoglobin Testing System. For In Vitro Diagnostic Use.

The Bio-Rad D. $1 0 ^ { \mathrm { T M } }$ Dual Program system is intended for the percent determination of hemoglobins Alc, A2 and F, and for the detection of abnormal hemoglobins in human whole blood using ion-exchange high performance liquid chromatography (HPLC).

The Bio-Rad D. $1 0 ^ { \mathrm { T M } }$ Dual Program is intended for Professional Use Only. For in vitro diagnostic use.

Measurement of the percent hemoglobin $\mathrm { A } _ { \mathrm { l c } }$ is effective in monitoring long-term glucose control in individuals with diabetes mellitus, and measurement of the percent $\mathrm { H b A } _ { 2 }$ and HbF are effective in screening of βthalassemias (i.e., hereditary hemolytic anemias characterized by decreased synthesis of one or more types of abnormal hemoglobin polypeptide chains).

Detection of hemoglobin variants such as hemoglobins S, C, D and E by HPLC is effective in presumptive identification of these variants.

# New Device Description

The Bio-Rad Hemoglobin Testing System is a fully automated analyzer consisting of a single module that provides an integrated method for sample preparation, separation, and determination of specific hemoglobins in whole blood. The Bio-Rad Hemoglobin Testing System provides an integrated method for the separation and determination of the relative percent of specific hemoglobins (e.g. A2, F and Alc in whole blood). The separation is based on the principles of high performance liquid chromatography. The system can accommodate 1 to 10 samples per run using a single rack currently.

The new feature in this submission is the optional D-10 Rack Loader which will be available for use with the D-10 Hemoglobin Testing System. The D-10 Rack Loader accommodates 5 racks and automatically transports each rack into and out of the D-10 System. The D-10 Rack Loader offers continuous loading, allowing the operator to insert or remove racks during a run.

# Technical Characteristics Compared to Predicate

The Bio-Rad D. $1 0 ^ { \mathsf { ^ { T M } } }$ Hemoglobin A1c Program and the D-10 Dual Program run on the D-10 Hemoglobin Testing System with D-10 Rack Loader have the same basic technical characteristics as the predicates D-10 Hemoglobin A1c Program (k) 031043 and D-10 Dual Program (k)041444 run on the D-10 Hemoglobin Testing System. There are three main differences between the D-10 Hemoglobin Testing System with the new D-10 Rack Loader. The technical characteristics are summarized in the following tables:

# D-10TM Hemoglobin A1c (k)031043

<table><tr><td rowspan=1 colspan=3>Summary of Technological Characteristic Similarities in Comparison to Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>New Device:D-IOTM Hemoglobin Alc Program run on theD-10 Hemoglobin Testing System withD-10 Rack Loader</td><td rowspan=1 colspan=1>Predicate Device:D-1OTM Hemoglobin Alc Program run on theD-10 Hemoglobin Testing System without theD-10 Rack Loader</td></tr><tr><td rowspan=1 colspan=1>Intended Use(s)</td><td rowspan=1 colspan=1>The Bio-Rad Hemoglobin Alc Program isintended for the percent determination ofhemoglobin Alc in human whole blood usingion-exchange high-performance liquidchromatography (HPLC). The D-10Hemoglobin Alc Program is intended for useonly with the Bio-Rad D-10 HemoglobinTesting System.For In Vitro Diagnostic Use.</td><td rowspan=1 colspan=1>The Bio-Rad Hemoglobin Alc Program isintended for the percent determination ofhemoglobin Alc in human whole blood usingion-exchange high-performance liquidchromatography (HPLC). The D-10Hemoglobin Alc Program is intended for useonly with the Bio-Rad D-10 HemoglobinTesting System.For In Vitro Diagnostic Use.</td></tr><tr><td rowspan=1 colspan=1>Indication(s) for Use</td><td rowspan=1 colspan=1>Measurement of the percent hemoglobin Alc iseffective in monitoring long-term glucosecontrol in individuals with diabetes mellitus.</td><td rowspan=1 colspan=1>Measurement of the percent hemoglobin Alc iseffective n monitoring long-term glucose controlin individuals with diabetes mellitus.</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>Cation exchange high performance liquidchromatography</td><td rowspan=1 colspan=1>Cation exchange high performance liquidchromatography</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human anticoagulated whole blood (EDTA)</td><td rowspan=1 colspan=1>Human anticoagulated whole blood (EDTA)</td></tr><tr><td rowspan=1 colspan=1>Visible Detection</td><td rowspan=1 colspan=1>415 nm</td><td rowspan=1 colspan=1>415 nm</td></tr><tr><td rowspan=1 colspan=1>Standardization</td><td rowspan=1 colspan=1>Traceable to the Diabetes Control andComplications Trial (DCCT) reference methodand IFCC. Certified via the NationalGlycohemoglobin Standardization Program(NGSP) for HbAlc.</td><td rowspan=1 colspan=1>Traceable to the Diabetes Control andComplications Trial (DCCT) reference methodand IFCC. Certified via the NationalGlycohemoglobin Standardization Program(NGSP) for HbAtc.</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Quantitative Area % HbAic</td><td rowspan=1 colspan=1>Quantitative Area % HbAlc</td></tr><tr><td rowspan=1 colspan=1>Time to processsample</td><td rowspan=1 colspan=1>3.0 minutes</td><td rowspan=1 colspan=1>3.0 minutes</td></tr></table>

# D-10TM Hemoglobin A1c (k)031043

<table><tr><td rowspan=1 colspan=3>Summary of Technological Characteristic Differences in Comparison to Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>New Device:D-10TM Hemoglobin Alc Program run on theD-10 Hemogiobin Testing System withD-10 Rack Loader</td><td rowspan=1 colspan=1>Predicate Device:D-1OTM Hemoglobin Alc Program run on theD-10 Hemoglobin Testing System without theD-10 Rack Loader</td></tr><tr><td rowspan=1 colspan=1>Software version</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.00</td></tr><tr><td rowspan=1 colspan=1>Number of Racks thatcan be run.</td><td rowspan=1 colspan=1>5 Racks of 10 EDTA whole blood tubes</td><td rowspan=1 colspan=1>1 rack of 10 EDTA whole blood tubes</td></tr><tr><td rowspan=1 colspan=1>Rack insertion intoD-10 HemoglobinTesting System</td><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Manual</td></tr></table>

D-10TM Dual Program (k)0414444   

<table><tr><td rowspan=2 colspan=3>Summary of Technological Characteristic Similarities in Comparison to Predicate Device</td></tr><tr></tr><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>New Device:Bio-Rad D-10TM Dual Program run on the D-10 Hemoglobin Testing System withD-10 Rack Loader</td><td rowspan=1 colspan=1>Predicate Device:Bio-Rad D-10 Dual Program run on the D-10Hemoglobin Testing System withoutD-10 Rack Loader</td></tr><tr><td rowspan=1 colspan=1>Intended Uscs</td><td rowspan=1 colspan=1>The Bio-Rad D-10 Dual Program system is intendedfor the percent determination of hemoglobins A1c,A and F, and for the detection of abnormalhemoglobins in human whole blood using ion-exchange high performance liquid chromatography(HPLC).The Bio-Rad D-10 Dual Program is intended forProfessional Use Only. For in vitro diagnostic use.</td><td rowspan=1 colspan=1>The Bio-Rad D-10 Dual Program system is intendedfor the percent determination of hemoglobins Ac, Aand F, and for the detection of abnormal hemoglobinsin human whole blood using ion-exchange highperformance liquid chromatography (HPLC).The Bio-Rad D-10 Dual Program is intended forProfessional Use Only. For in vitro diagnostic use.</td></tr><tr><td rowspan=1 colspan=1>Indication(s) for Use</td><td rowspan=1 colspan=1>Measurement of the percent hemoglobin Ac iseffective in monitoring long-term glucose control inindividuals with diabctes mellitus, and measurementof the percent HbA2 and HbF are effective inmonitoring of B-thalassemia (i.e., hereditaryhemolytic anemias characterized by decreasedsynthesis of one or more types of abnormalhemoglobin polypeptide chains).Detection of hemoglobin variants such ashemoglobins S, C, D and E by HPLC is effective inpresumptive identification of these variants.</td><td rowspan=1 colspan=1>Measurement of the percent hemoglobin Alc iseffective in monitoring long-term glucose control inindividuals with diabetes mellitus, and measurementof the percent HbA and HbF are effective inmonitoring of B-thalassemia (i.e., hereditaryhemolytic anemias characterized by decreasedsynthesis of one or more types of abnormalhemoglobin polypeptide chains).Detection of hemoglobin variants such ashemoglobins S, C, D and E by HPLC is effective inpresumptive identification of these variants.</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>Cation exchange high performance liquidchromatography</td><td rowspan=1 colspan=1>Cation exchange high performance liquidchromatography</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human anticoagulated whole blood (EDTA)</td><td rowspan=1 colspan=1>Human anticoagulated whole blood (EDTA)</td></tr><tr><td rowspan=1 colspan=1>Visible Detection</td><td rowspan=1 colspan=1>415 nm</td><td rowspan=1 colspan=1>415 nm</td></tr><tr><td rowspan=1 colspan=1>Standardization</td><td rowspan=1 colspan=1>Traceable to the Diabetes Control andComplications Trial (DCCT) reference method andIFCC. Certified via the National GlycohemoglobinStandardization Program (NGSP) for HbA 1c.The Joint Committee on Traceability in LaboratoryMedicine has not identified a higher order refcrencemethod or reference material for the quantitation ofHbA2 and HbF</td><td rowspan=1 colspan=1>Traceable to the Diabetes Control and ComplicationsTrial (DCCT) reference method and IFCC. Certifiedvia the National Glycohemoglobin StandardizationProgram (NGSP) for HbA1c.The Joint Committee on Traceability in LaboratoryMedicine has not identified a higher order referencemethod or reference material for the quantitation ofHbA2 and HbF</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Quantitative Area % HbA2 F and A Ic</td><td rowspan=1 colspan=1>Quantitative Area % HbA2 Fand Alc</td></tr><tr><td rowspan=1 colspan=1>Time to process sample</td><td rowspan=1 colspan=1>6.5 minutes</td><td rowspan=1 colspan=1>6.5 minutes</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td></tr></table>

# D-10TM Dual Program (k)0414444

<table><tr><td rowspan=1 colspan=3>Summary of Technological Characteristic Differences in Comparison to Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>New Device:D-IOTM Hemoglobin Alc Program run on theD- 10 Hemoglobin Testing System withD-10 Rack Loader</td><td rowspan=1 colspan=1>Predicate Device:D-1OTM Hemoglobin Alc Program run on theD-10 Hemoglobin Testing System without theD-10 Rack Loader</td></tr><tr><td rowspan=1 colspan=1>Software version</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.00</td></tr><tr><td rowspan=1 colspan=1>Number of Racks thatcan be run.</td><td rowspan=1 colspan=1>5 Racks of 10 EDTA whole blood tubes</td><td rowspan=1 colspan=1>I rack of 10 EDTA whole blood tubes</td></tr><tr><td rowspan=1 colspan=1>Rack insertion intoD-10 HemoglobinTesting System</td><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Manual</td></tr></table>

# Testing To Establish Substantial Equivalence:

Note: The D-10 Hemoglobin Testing System currently contains one rack for 10 EDTA Whole Blood Tubes for small laboratories. Throughout this document the text will indicate either the D-10 Hemoglobin A1c Program or D-10 Dual Program are run with or without the D-10 Rack Loader on the D-10 Hemoglobin Testing System. The D-10 Rack Loader is an optional accessory item to the D-10 Hemoglobin Testing System that allows for 5 racks of 10 EDTA Whole Blood Tubes to be run automatically while the system is running in mid size laboratories.

# Accuracy:

# D-10 Hemoglobin HbA1c Program (3 minute)

Method correlation between Bio-Rad D-10 Hemoglobin AIc Program with D-10 Rack Loader and D-10 Hemoglobin Alc Program without D-10 Rack Loader was evaluated using 40 EDTA whole blood samples ranging from 5.1% -14.3% HbA1c. The results are presented in the following table:

D-10 Hemoglobin A1c Program Correlation for HbA1c   

<table><tr><td rowspan=1 colspan=1>Regression Method</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>$r2}$</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>Least Squares</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.9950</td><td rowspan=1 colspan=1>0.9415</td><td rowspan=1 colspan=1>0.2714</td></tr></table>

# D-10 Dual Program -Hemoglobin A1c (6.5 minute)

Method correlation between Bio-Rad D-10 Dual Program with D-10 Rack Loader and D-10 Dual Program without D-10 Rack was evaluated using 40 EDTA whole blood samples ranging from 5.1% to 14.3% HbAjc. The results are presented in the following table:

D-10 Dual Program Correlation for HbA1c   

<table><tr><td rowspan=1 colspan=1>Regression Method</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>2}$</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>Least Squares</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.9956</td><td rowspan=1 colspan=1>0.9827</td><td rowspan=1 colspan=1>0.1208</td></tr></table>

# D-10 Dual Program - Hemoglobin A2 (6.5 minute)

Method correlation between Bio-Rad D-10 Dual Program with D-10 Rack Loader and D-10 Dual Program without Rack Loader was evaluated with 39 EDTA whole blood samples ranging from 2.1% - 11.8% HbA2. The results are presented in the following table:

D-10 Dual Program Correlation for HbA2   

<table><tr><td rowspan=1 colspan=1>Regression Method</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>$r^2}$</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>Least Squares</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>0.9975</td><td rowspan=1 colspan=1>0.9902</td><td rowspan=1 colspan=1>0.2476</td></tr></table>

# D-10 Dual Program - Hemoglobin F (6.5 minute)

Method correlation between Bio-Rad D-10 Dual Program with D-10 Rack Loader and D-10 Dual Program without D-10 Rack Loader was evaluated with 39 EDTA whole blood samples ranging from 0.8% - 17.3% HbF. The results are presented in the following table:

$\mathbf { D } \mathbf { - } \mathbf { 1 0 } ^ { \mathrm { T M } }$ Dual Program Correlation for HbF   

<table><tr><td rowspan=1 colspan=1>Regression Method</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>$r^2}$</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>Least Squares</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>0.9956</td><td rowspan=1 colspan=1>1.0188</td><td rowspan=1 colspan=1>-0.3863</td></tr></table>

# Precision:

# D-10 Hemoglobin A1c Program (3 minute)

The following precision table provides comparison data on the precision between D-10 Hemoglobin A1c Program with the D-10 and Rack Loader and the D-10 Hemoglobin Alc Program without the D-10 Rack Loader, each utilizing EDTA whole blood patient samples.

Method precision was performed using a protocol based on the NCCLS Evaluation protocol, EP5-A2 for the D-10 Hemoglobin Alc Program with D-10 Rack Loader and NCCLS Evaluation protocol EP5-T2 for the D-10 Hemoglobin Ac Program without Rack Loader. The protocols for both the D-10 Hemoglobin Alc Program with D-10 Rack Loader and D-10 Hemoglobin $\mathbf { A } _ { 1 c }$ Programs without D-10 Rack Loader are similar. Using these protocols, two samples were run on one rack, twice a day over 20 working days on one D-10 Hemoglobin Testing System without D10 Rack Loader. On the D-10 Hemoglobin Testing System with D-10 Rack Loader, the protocol requires two samples run on each of five racks, twice a day over 20 working days. In each duplicate daily run for both verification studies, duplicate aliquots of normal HbAlc and diabetic HbAlc patient samples were each analyzed per run. Although the precision samples are different, since they were run at different time periods, the precision results between the D-10 Hemoglobin A1c Program with D-10 Rack Loader and the D-10 Hemoglobin A1c Program without D-10 Rack Loader are equivalent. A summary of combined comparative precision results is presented in the following precision table.

D-10 HbA1c with D-10 Rack Loader vs. D-10 HbA1c without D-10 Rack Loader - Precision   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>D-10 HbA1cwith D-10 Rack Loader</td><td rowspan=1 colspan=2>D-10 HbA1cwithout D-10 Rack Loader</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Normal Sample Diabetic Sample</td><td rowspan=1 colspan=1>Normal Sample Diabetic Sample</td><td rowspan=1 colspan=1>Normal Sample Diabetic Sample</td><td rowspan=1 colspan=1>Normal Sample Diabetic Sample</td></tr><tr><td rowspan=1 colspan=1>n= (number of samples)</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Mean (%HbAic)</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>13.1</td></tr><tr><td rowspan=1 colspan=1>Within run (%CV)</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Total Precision (%CV)</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.9</td></tr></table>

# D-10 Dual Program $\blacktriangleright$ HbA1c (6.5 minutes)

The following precision table provides comparison data on the precision between D-10 Dual Program (HbA1c) with Rack Loader and the D-10 Dual Program (HbA1c) without the D-10 Rack Loader, each utilizing EDTA whole blood patient samples.

Method precision was performed using a protocol based on the NCCLS Evaluation protocol EP5- A2 for the D-10 Dual Program with D-10 Rack Loader and NCCLS Evaluation protocol EP5-A for the D-10 Dual Program without Rack Loader. The protocols for both the D- $\mathrm { \hat { \ l } 0 ^ { \mathrm { { T M } } } }$ Dual Program with D-10 Rack Loader and D-10 Dual Program without D-10 Rack Loader are similar. Using these protocols, two samples were run on one rack, twice a day over 20 working days on one D-10 Hemoglobin Testing System. On the D-10 Hemoglobin Testing System with D-10 Rack Loader, the protocol requires two samples run on each of five racks, twice a day over 20 working days. In each duplicate daily run for both verification studies, duplicate aliquots of normal $\mathrm { H b A } _ { 1 \mathrm { c } }$ and diabetic HbAlc patient samples were each analyzed per run. Although the precision samples are different, since they were run at different time periods, the precision results between the D-10

Dual Program with D-10 Rack Loader and the D-10 Dual Program without D-10 Rack Loader are equivalent. A summary of combined comparative precision results is presented in the following precision table.

# D-10 Dual Program (HbA1c) with D-10 Rack Loader vs. D-10 Dual Program (HbA1c) without D-10 Rack Loader - Precision

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>D-10 Dual (6.5 Minutes)HbA 1c Program with D-10 RackLoader</td><td rowspan=1 colspan=2>D-10 Dual (6.5 Minutes)HbA1c Program without D-10Rack Loader</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Normal Sample  Diabetic Sample</td><td rowspan=1 colspan=1>Normal Sample  Diabetic Sample</td><td rowspan=1 colspan=1>Normal SampleDiabetic Sample</td><td rowspan=1 colspan=1>Normal SampleDiabetic Sample</td></tr><tr><td rowspan=1 colspan=1>n= (number of samples)</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Mean (%HbAtc)</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>13.1</td></tr><tr><td rowspan=1 colspan=1>Within run (%CV)</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Total Precision (%CV)</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.9</td></tr></table>

# D-10 Dual Program HbA2 (6.5 minutes)

The following precision table provides comparison data on the precision between D-10 Dual Program (HbA2) with D-10 Rack Loader and D-10 Dual Programs (HbA2) without D-10 Rack Loader, each utilizing EDTA whole blood patient samples.

Method precision was performed using a protocol based on the NCCLS Evaluation protocol EP5- A2 for the D-10 Dual Program with D-10 Rack Loader and NCCLS Evaluation protocol EP5-A for the D-10 Dual Program without Rack Loader. The protocols for both the D-10 Dual Program with D-10 Rack Loader and D-10 Dual Program without D-10 Rack Loader are similar. Using these protocols, two samples were run on one rack, twice a day 40 runs over 20 working days were performed on one D-10 Hemoglobin Testing System. On the D-10 Hemoglobin Testing System with D-10 Rack Loader, the protocol requires two samples run on each of five racks, twice a day over 20 working days. In each duplicate daily run for both verification studies, duplicate aliquots of low HbA2 and high HbA2 patient samples were each analyzed per run. Although the precision samples are different, since they were run at different time periods, the precision results between the D-10 Dual Program with D-10 Rack Loader and the D-10 Dual Program without D-10 Rack Loader are equivalent. A summary of combined comparative precision results is presented in the following precision table.

Precision: (continued)

# D-10 Dual Program (HbA2) with D-10 Rack Loader vs. D-10 Dual Program (HbA2) without D-10 Rack Loader - Precision

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>D-10 Dual Program (6.5 Minutes)HbA2 run with D-10 Rack Loader</td><td rowspan=1 colspan=2>VARIANT II β-thalassemia ShortHbA2 run without D-10 Rack Loader</td></tr><tr><td rowspan=1 colspan=1>SS</td><td rowspan=1 colspan=1>Low Sample</td><td rowspan=1 colspan=1>High Sample</td><td rowspan=1 colspan=1>Low Sample</td><td rowspan=1 colspan=1>High Sample</td></tr><tr><td rowspan=1 colspan=1>n= (number of samples)</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Mean (%HbA2)</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>Within run (%CV)</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Total Precision (%CV)</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>3.1</td></tr></table>

# D-10 Dual Program - HbF (6.5 minutes)

The following precision table provides comparison data on the precision between D-10 Dual Program (HbF) with the D-10 Rack Loader and the D-10 Dual Program (HbF) without D-10 Rack Loader, each utilizing EDTA whole blood patient samples.

Method precision was performed using a protocol based on the NCCLS Evaluation protocol EP5- A2 for the D-10 Dual Program with D-10 Rack Loader and NCCLS Evaluation protocol EP5-A for the D-10 Dual Program without Rack Loader. The protocols for both the D-10 Dual Program with D-10 Rack Loader and D-10 Dual Program without D-10 Rack Loader are similar. Using these protocols, two samples were run on one rack, twice a day over 20 working days on one D10 Hemoglobin Testing System. On the D-10 Hemoglobin Testing System with D-10 Rack Loader, the protocol requires two samples run on each of five racks, twice a day over 20 working days. In each duplicate daily run for both verification studies, duplicate aliquots of low HbF and high HbF patient samples were each analyzed per run. Although the precision samples are different, since they were run at different time periods, the precision results between the D-10 Dual Program with D-10 Rack Loader and the D-10 Dual Program without D-10 Rack Loader are equivalent. A summary of combined comparative precision results is presented in the following precision table.

D-10 Dual Program (HbF) with D-10 Rack Loader vs. D-10 Dual Program (HbF) without D-10 Rack Loader - Precision   

<table><tr><td rowspan=1 colspan=1>3PR.</td><td rowspan=1 colspan=2>D-10 Dual Program (6.5 minutes)HbF with D-10 Rack Loader</td><td rowspan=1 colspan=2>D-10 Dual Program (6.5 minutes)HbF without D-10 Rack Loader</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>Low Sample</td><td rowspan=1 colspan=1>High Sample</td><td rowspan=1 colspan=1>Low Sample</td><td rowspan=1 colspan=1>High Sample</td></tr><tr><td rowspan=1 colspan=1>n= (number of samples)</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Mean (%HbF)</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>Within run (%CV)</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Total Precision (%CV)</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>2.0</td></tr></table>

# Conclusion:

The similarities of the intended use and the general performance characteristics and results of the newly described and evaluated D-10 Hemoglobin A1c Program and D-10 Dual Program with D-10 Rack Loader on the D-10 Hemoglobin Testing system are nearly identical to or logical extensions of those for the two cleared predicate program systems [i.e., the Bio-Rad D-10 Hemoglobin Aic Program and the Bio-Rad Dual Program]. Thus, one may conclude, based on the use of the same HPLC technology, and the nearly equivalent results obtained for the correlation and precision versus the corresponding results obtained with the two predicate systems that the new D-10 Hemoglobin A1c Program and D-10 Dual Program with D-10 Rack Loader on the D-10 Hemoglobin Testing system is substantially equivalent to these 2 cleared and currently marketed predicate systems.

Ms. Jackie Buckley   
Regulatory Affairs Representative Bio-Rad Laboratories, Inc.   
Clinical Systems Division   
4000 Alfred Nobel Dr.   
Hercules, CA 94547

Re: k060001 Trade/Device Name: Bio-Rad D-10TM Dual Program and D-10 Hemoglobin A1c Program run on the D-10 Hemoglobin Testing System with D-10 Rack Loader Regulation Number: 21 CFR§864.7470 Regulation Name: Glycosylated hemoglobin assay Regulatory Class: Class II Product Code: LCP, JPD Dated: December 30, 2005 Received: January 3, 2006

Dear: Ms. Buckley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/6ce2dc590c8862f6c716d393a9d2acccfbf32654e4a28b2c25e4b43445939de5.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known):_K060001

Device Name:

Bio-Rad D $1 0 ^ { \mathsf { T M } }$ Dual Program and D-10 Hemoglobin $A _ { 1 0 }$ Program run on the D-10 Hemoglobin Testing System with D-10 Rack Loader

Indications For Use:

Measurements of percent $H b A _ { 1 c }$ are effective in monitoring long-term glucose control in individuals with diabetes mellitus.

Measurement of percent ${ \mathsf { H b } } { \mathsf { A } } _ { 2 }$ and HbF are used for evaluation $\beta$ — thalassemia, a hereditary hemolytic anemia.

Detection of hemoglobin variants such as S, C, D and E are effective in presumptive identification.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Office of In Vitro Diagnostic Device Evaluation and Safety

K060001